Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.56 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16264850 | 0.95 | MEN1 (0.60) | MEN1KMT2AL3MBTL1BRD4CYSLTR2 | |
| SCHEMBL14570538 | 0.93 | MEN1 (0.59) | MEN1KMT2AL3MBTL1BRD4CYSLTR2 | |
| SCHEMBL3951838 | 0.91 | L3MBTL1 (0.66) | MEN1KMT2AL3MBTL1LTA4HTSHR | |
| SCHEMBL3466988 | 0.88 | CYSLTR2 (0.59) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL8981963 | 0.88 | BRD4 (0.56) | L3MBTL1BRD4CYSLTR2CYSLTR1LTA4H | |
| SCHEMBL13763460 | 0.87 | TP53 (0.56) | MEN1KMT2AL3MBTL1HTTTSHR | |
| SCHEMBL12549253 | 0.87 | LTA4H (0.59) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL3257350 | 0.87 | BRD4 (0.54) | BRD4CYSLTR2CYSLTR1LTA4HMAPT | |
| SCHEMBL3267566 | 0.87 | BRD4 (0.54) | L3MBTL1BRD4CYSLTR2CYSLTR1LTA4H | |
| SCHEMBL1623579 | 0.87 | BRD4 (0.54) | BRD4CYSLTR2CYSLTR1LTA4HMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| WO-2011150079-A1 | TARGETED PROBES OF CELLULAR PHYSIOLOGY | CARNEGIE MELLON UNIVERSITY (US) | 2011-12-01 | — | — | WO | disclosed |
| CN-1190441-C | Phosphine sulfide preparing process and use thereof | MITSUI CHEMICALS INC (JP) | 2005-02-23 | — | — | CN | disclosed |
| EP-0972776-B1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | MITSUI CHEMICALS INC (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6153794-A | Phosphine sulfide, a manufacturing process therefor and use thereof | MITSUI CHEMICALS, INC. (JP) | 2000-11-28 | — | — | US | disclosed |
| CN-1262276-A | Phosphine sulfide preparing process and use thereof | MITSUI CHEMICALS INC (JP) | 2000-08-09 | — | — | CN | disclosed |
| EP-0972776-A1 | A phosphine sulfide, a manufacturing process therefor and a use thereof | Mitsui Chemicals, Inc. (JP) | 2000-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | MEN1 3545/4885KMT2A 2201/4885L3MBTL1 3485/4885 |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | MEN1 3545/4885KMT2A 2201/4885L3MBTL1 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.